Prosecution Insights
Last updated: April 19, 2026

Examiner: MEYERING, SHABANA SHABBEER

Tech Center 1600 • Art Units: 1635 1636

This examiner grants 70% of resolved cases

Performance Statistics

69.6%
Allow Rate
+9.6% vs TC avg
106
Total Applications
+40.5%
Interview Lift
834
Avg Prosecution Days
Based on 56 resolved cases, 2023–2026

Rejection Statute Breakdown

5.8%
§101 Eligibility
10.4%
§102 Novelty
34.0%
§103 Obviousness
33.1%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17262342 GENE EDITING OF ANTICOAGULANTS Final Rejection TOOLGEN INCORPORATED
17845535 USE OF SARAF INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION Non-Final OA Hoffmann-La Roche Inc.
19271317 COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID Non-Final OA Wyvern Pharmaceuticals Inc.
17810022 METHODS FOR THE TREATMENT OF EPILEPSY Non-Final OA CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
17597351 METHODS FOR THE TREATMENT OF EPILEPSY Final Rejection CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
17701013 MULTI-INPUT MIRNA SENSING WITH CONSTITUTIVE ERNS TO REGULATE MULTI-OUTPUT GENE EXPRESSION IN MAMMALIAN CELLS Final Rejection Massachusetts Institute of Technology
17974805 TOPOLOGIES OF SYNTHETIC GENE CIRCUIT FOR OPTIMAL FOLD CHANGE ACTIVATION Final Rejection TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED
19022242 DIGITAL COUNTING OF INDIVIDUAL MOLECULES BY STOCHASTIC ATTACHMENT OF DIVERSE LABELS Non-Final OA Becton, Dickinson and Company
18306511 Method and Reagents for Reprogramming Endothelial Cells Non-Final OA University of Pittsburgh - Of the Commonwealth System of Higher Education
17904095 NOVEL COMBINATION OF NUCLEIC ACID REGULATORY ELEMENTS AND METHODS AND USES THEREOF Final Rejection VRIJE UNIVERSITEIT BRUSSEL
18248363 HOMOGENEOUS BETA-1,3-GLUCAN/NUCLEIC ACID COMPLEXES AND USE THEREOF Non-Final OA The University of Kitakyushu
18027476 FOXP3S-PROMOTING MORPHOLINOS Non-Final OA THE TRUSTEES OF INDIANA UNIVERSITY
17766998 COMPOSITIONS AND METHODS FOR HOMOLOGY-DIRECTED RECOMBINATION Non-Final OA LIFE TECHNOLOGIES CORPORATION
18467442 METHODS AND COMPOSITIONS FOR REJUVENATING CNS GLIAL POPULATIONS BY SUPPRESION OF TRANSCRIPTION FACTORS Final Rejection UNIVERSITY OF ROCHESTER
17835671 NUCLEIC ACID CONSTRUCTS ENCODING KALLIKREIN-2 FUSION PROTEIN AND VECTORS, PREPARATIONS OF CELLS, AND METHODS OF USE THEREOF Final Rejection Janssen Biotech, Inc.
18734879 Guide Strand Library Construction and Methods of Use Thereof Non-Final OA Pioneer Biolabs, LLC
17605788 Flea Beetle-Specific RNAI-Based Pesticides Final Rejection University of Manitoba
17995568 COMPOSITIONS AND METHODS FOR SILENCING MYOC EXPRESSION Non-Final OA ALNYLAM PHARMACEUTICALS, INC.
17755165 NUCLEIC ACID DELIVERY ENHANCER Final Rejection TOKYO UNIVERSITY OF SCIENCE FOUNDATION
18175394 ENGINEERED MICROALGAE FEED TO IMPROVE HONEY BEE PATHOGEN RESISTANCE AND NUTRITION Non-Final OA The United States of America, as represented by The Secretary of Agriculture
18311789 METHOD OF TREATING DUCHENNE MUSCULAR DYSTROPHY Non-Final OA BioMarin Pharmaceutical Inc.
17214436 IMMUNORESPONSIVE CELLS EXPRESSING DOMINANT NEGATIVE FAS AND USES THEREOF Non-Final OA THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC
18249036 COMPOSITION FOR TREATING RETINAL OR CHOROIDAL DISEASES, CONTAINING ACTA2 INHIBITOR AS ACTIVE INGREDIENT Non-Final OA AMC SCIENCES CO., LTD
18040803 NUCLEIC ACID THERAPY FOR DIFFERENTIAL MODULATION OF HOST MICROFLORA Non-Final OA Michael STALHAMER
18098883 SYNTHETIC RNA FRAGMENT AND ITS USES FOR RNA-DEPENDENT AMPLIFICATION Non-Final OA MELLO BIOTECH TAIWAN CO., LTD.
17604332 STABLE TARGETED INTEGRATION Non-Final OA Sigma-Aldrich Co. LLC
18000197 Biomarkers Related to Oral Squamous Cell Carcinoma and Methods of Diagnosis and Treatment Thereof Non-Final OA QINGDAO MEDINTELL BIOMEDICAL CO., LTD
17985963 METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF GAP JUNCTION PROTEIN BETA 2 (GJB2) Non-Final OA Korro Bio, Inc.
17299186 METHODS FOR THE TREATMENT OF TRINUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH MSH3 ACTIVITY Final Rejection TAKEDA PHARMACEUTICALS U.S.A., INC.
17800806 ARCHAEAL PYRROLYSYL TRNA SYNTHETASES FOR ORTHOGONAL USE Non-Final OA European Molecular Biology Laboratory

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month